Elizabeth Berger

Dr. Elizabeth Berger


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 August 2021 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
EBElizabeth Berger
Elizabeth Berger
TPTristen Park
Tristen Park
ASAngeleke Saridakis
Angeleke Saridakis
MGMehra Golshan
Mehra Golshan
RGRachel A. Greenup
Rachel A. Greenup
Nita AhujaNita Ahuja
Nita Ahuja
Triple-negative breast cancer (TNBC) is considered one of the highest-risk subtypes of breast cancer and has dismal prognosis. Local recurrence rate after standard therapy in the early breast cancer setting can be upwards to 72% in 5 years, and in the metastatic setting, the 5-year overall survival is 12%. Due to the lack of receptor expression, there has been a paucity of targeted therapeutics available, with chemotherapy being the primary option for systemic treatment in both the neoadjuvant and metastatic setting. More recently, immunotherapy has revolutionized the landscape of cancer treatment, particularly immune checkpoint inhibitor (ICI) therapy, with FDA approval in over 20 types of cancer since 2011. Compared to other cancer types, breast cancer has been traditionally thought of as being immunologically cold; however, TNBC has demonstrated the most promise with immunotherapy use, a timely discovery due to its lack of targeted therapy options. In this review, we summarize the trials using checkpoint therapy in early and metastatic TNBC, as well as the development of biomarkers and the importance of immune related adverse events (IRAEs), in this disease process.

1 January 2021 in The Cancer Journal
Verified
Journal Article
Closed access
EBElizabeth Berger
Elizabeth Berger
NINeil M. Iyengar
Neil M. Iyengar
Obesity is an increasingly prevalent state of energy imbalance that contributes to breast cancer risk and outcomes. The effects of obesity differ by breast cancer subtype and menopause. While most studies have focused on postmenopausal hormone receptor–positive disease, less is known about the relationship between obesity and triple-negative breast cancer (TNBC). Here we will review the observations linking obesity to TNBC, the socioeconomic disparities that contribute to obesity-related TNBC, and putative biologic mechanisms. Finally, we will consider the impact of obesity on surgical and medical treatment of TNBC and novel strategies to improve energy balance after cancer diagnosis.

31 August 2021 in Genes
Verified
Journal Article
Open access
PDF file
EBElizabeth Berger
Elizabeth Berger
MGMehra Golshan
Mehra Golshan
The identification that breast cancer is hereditary was first described in the nineteenth century. With the identification of the BRCA1 and BRCA 2 breast/ovarian cancer susceptibility genes in the mid-1990s and the introduction of genetic testing, significant advancements have been made in tailoring surveillance, guiding decisions on medical or surgical risk reduction and cancer treatments for genetic variant carriers. This review discusses various medical and surgical management options for hereditary breast cancers.

2 November 2023 in JMIR Cancer
Verified
Journal Article
Open access
VMVictoria A Marks
Victoria A Marks
WHWalter R Hsiang
Walter R Hsiang
JNJames Nie
James Nie
WUWaez Umer
Waez Umer
AHAfash Haleem
Afash Haleem
MLMichael S Leapman
Michael S Leapman
Background: Telehealth was an important strategy for maintaining continuity of cancer care during the coronavirus pandemic and has continued to play a role in outpatient care; however, it is unknown whether services are equally available across cancer hospitals. Objective: This study aimed to assess telehealth availability at cancer hospitals for new and established patients with common cancers to contextualize the impact of access barriers to technology on overall access to health care. Methods: We conducted a national cross-sectional secret shopper study from June to November 2020 to assess telehealth availability at cancer hospitals for new and established patients with colorectal, breast, and skin (melanoma) cancer. We examined facility-level factors to determine predictors of telehealth availability. Results: Of the 312 investigated facilities, 97.1% (n=303) provided telehealth services for at least 1 cancer site. Telehealth was less available to new compared to established patients (n=226, 72% vs n=301, 97.1%). The surveyed cancer hospitals more commonly offered telehealth visits for breast cancer care (n=266, 85%) and provided lower access to telehealth for skin (melanoma) cancer care (n=231, 74%). Most hospitals (n=163, 52%) offered telehealth for all 3 cancer types. Telehealth availability was weakly correlated across cancer types within a given facility for new (r=0.16, 95% CI 0.09-0.23) and established (r=0.14, 95% CI 0.08-0.21) patients. Telehealth was more commonly available for new patients at National Cancer Institute–designated facilities, medical school–affiliated facilities, and major teaching sites, with high total admissions and below-average timeliness of care. Telehealth availability for established patients was highest at Academic Comprehensive Cancer Programs, nongovernment and nonprofit facilities, medical school–affiliated facilities, Accountable Care Organizations, and facilities with a high number of total admissions. Conclusions: Despite an increase in telehealth services for patients with cancer during the COVID-19 pandemic, we identified differences in access across cancer hospitals, which may relate to measures of clinical volume, affiliation, and infrastructure.

26 September 2025 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Closed access
IRIlana B Richman
Ilana B Richman
MLMeghan E Lindsay
Meghan E Lindsay
JLJessica B Long
Jessica B Long
EEEliza Epstein
Eliza Epstein
MSMeera Sheffrin
Meera Sheffrin
EBElizabeth Berger
Elizabeth Berger
Background: Mammographic surveillance is common among older women with a history of breast cancer, but little is known about imaging outcomes in this population. The goal of this study was to describe short-term outcomes after surveillance mammography among older women, including use of subsequent imaging, cancer diagnosis, and positive predictive value. Methods: This longitudinal cohort study used Surveillance, Epidemiology and End Results–Medicare data. We followed women diagnosed with breast cancer between 2003 and 2007 at age 67 or older until diagnosis of a second primary breast cancer, death, or end of follow-up (2019). We used claims to identify surveillance mammograms. Outcomes included subsequent imaging, second primary breast cancer diagnosis, and positive predictive value after surveillance. Outcomes were identified based on proximity to surveillance mammography. We stratified analyses by age and time since diagnosis. Results: The cohort included 33 607 women who received 160 637 mammograms over a median of 12.1 years. Subsequent imaging was performed after 115 per 1000 mammograms (95% confidence interval [CI] = 114 to 117) and was similar across ages and time since diagnosis. Second primary breast cancer was diagnosed after 7.1 per 1000 mammograms (95% CI = 6.7 to 7.5) and was similar across ages but generally higher beginning 5 years postdiagnosis. Positive predictive value among women with subsequent imaging ranged from 3.7% to 9.2%. Most second primary breast cancers were either in situ (23.3%) or stage I (57.0%). Conclusions: Although surveillance mammography may detect breast cancer even years after diagnosis, surveillance also leads to substantial subsequent testing. Whether continued surveillance at older ages improves health outcomes is uncertain.

19 July 2021 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Open access
PDF file
SSSally Spencer
Sally Spencer
OHOliver Hamer
Oliver Hamer
EBElizabeth Berger
Elizabeth Berger
ABAndrew Booth
Andrew Booth
GIGreg J Irving
Greg J Irving
CKCarol Kelly
Carol Kelly
Objectives This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To evaluate the impact of interventions to improve inhaler technique on performance and clinical outcomes in people with COPD.